Abstract | OBJECTIVE: METHODS: RESULTS: After 24 weeks, the BMD values at lumbar spine, femoral neck, major trochanter, and Ward' s triangle increased by 6.1%, 6.3%, 3.3%, and 2.2% respectively compared with those at baseline (all P<0.05), however, those of the control group decreased by 8.7%, 9.1%, 7.7%, and 6.4% respectively (P<0.01, P<0.05), and the BMD levels at lumbar spine and femoral neck 24 weeks later of the Alen + calcium group were both higher than those of the control group (P<0.01, P<0.05). 24 weeks later the level of urine cross linked N-telopeptides of type I collagen (NTX) of the Alen + calcium group decreased (P<0.05), and the blood osteocalcin (BGP) of the Alen + calcium group increased, however, not significantly (P>0.05). There were no significant differences in serum AKP and BGP and urine NTX 24 weeks later between these 2 groups. CONCLUSION:
|
Authors | Qiao-hong Wang, Hua-xiang Wu, Yong-lu Huang, Jing Xue, Xu-yan Yang, Liang Zhu, Li-hong Wen |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 88
Issue 27
Pg. 1888-91
(Jul 15 2008)
ISSN: 0376-2491 [Print] China |
PMID | 19040000
(Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Bone Density Conservation Agents
- Glucocorticoids
- Alendronate
|
Topics |
- Adult
- Alendronate
(therapeutic use)
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(therapeutic use)
- Female
- Glucocorticoids
(adverse effects, therapeutic use)
- Humans
- Lupus Erythematosus, Systemic
(drug therapy)
- Male
- Middle Aged
- Osteoporosis
(chemically induced, physiopathology, prevention & control)
- Rheumatic Diseases
(drug therapy)
- Treatment Outcome
- Young Adult
|